Market Research Logo

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015’, provides an overview of the Idiopathic Pulmonary Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Idiopathic Pulmonary Fibrosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Idiopathic Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Idiopathic Pulmonary Fibrosis Overview
Therapeutics Development
Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview
Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis
Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies
Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
Idiopathic Pulmonary Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Idiopathic Pulmonary Fibrosis - Products under Development by Companies
Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
AdAlta Pty Ltd.
Aeolus Pharmaceuticals, Inc.
Afferent Pharmaceuticals, Inc.
AnaMar AB
Biogen, Inc.
Bioneer Corporation
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celgene Corporation
Chong Kun Dang Pharmaceutical Corp.
Compugen Ltd.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Galapagos NV
GenKyoTex S.A.
Gilead Sciences, Inc.
Global Blood Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Histocell S.L.
iBio, Inc.
ImmuneWorks, LLC
Inventiva SAS
Isarna Therapeutics GmbH
Kadmon Corporation, LLC
Kasiak Research Private Limited
Kyorin Pharmaceutical Co., Ltd.
LTT Bio-Pharma Co., Ltd.
MedImmune, LLC
Moerae Matrix, Inc.
MorphoSys AG
MSM Protein Technologies, Inc.
Pacific Therapeutics Ltd.
Pharmaxis Limited
Progenra, Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
Respira Therapeutics, Inc.
Rhizen Pharmaceuticals SA
Ribomic Inc.
Sanofi
Teva Pharmaceutical Industries Limited
Yuhan Corporation
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(pentoxifylline + acetylcysteine) - Drug Profile
AEOL-10150 - Drug Profile
AF-219 - Drug Profile
AM-0010 - Drug Profile
AMAP-102 - Drug Profile
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide for COPD and IPF - Drug Profile
Antisense RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile
BG-00011 - Drug Profile
BMS-986020 - Drug Profile
BOT-191 - Drug Profile
CC-539 - Drug Profile
CC-90001 - Drug Profile
CGEN-25009 - Drug Profile
CKD-942 - Drug Profile
CMYJH-01 - Drug Profile
CT-2009 - Drug Profile
D-9030 - Drug Profile
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile
FG-3019 - Drug Profile
GBT-1118 - Drug Profile
GBT-440 - Drug Profile
GKT-831 - Drug Profile
GLPG-1690 - Drug Profile
HC-016 - Drug Profile
HEC-00000585 - Drug Profile
HL-156FIB - Drug Profile
HR-017 - Drug Profile
IBIOCFB-03 - Drug Profile
ICG-001 - Drug Profile
ISTH-0047 - Drug Profile
IVA-337 - Drug Profile
IW-001 - Drug Profile
KBP-7018 - Drug Profile
KD-025 - Drug Profile
lebrikizumab - Drug Profile
LT-0011 - Drug Profile
LTI-03 - Drug Profile
MMI-0100 - Drug Profile
MOR-107 - Drug Profile
MSM-735 - Drug Profile
NAS-911 - Drug Profile
Neumomir - Drug Profile
OLX-201 - Drug Profile
P-013 - Drug Profile
PBF-1129 - Drug Profile
PBI-4050 - Drug Profile
PBI-4425 - Drug Profile
pirfenidone - Drug Profile
PRM-151 - Drug Profile
PUR-1500 - Drug Profile
PXS-4820 - Drug Profile
RBM-005 - Drug Profile
RBM-006 - Drug Profile
Refacell-IPF - Drug Profile
RP-6503 - Drug Profile
RT-234 - Drug Profile
SAR-156597 - Drug Profile
SD-560 - Drug Profile
simtuzumab - Drug Profile
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecule for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules for COPD and IPF - Drug Profile
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit LOXL2 for Oncology and Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit PTPN13 for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile
SPL-334 - Drug Profile
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
Stem Cell Therapy for Idiopathic Pulmonary Fibrosis - Drug Profile
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
TD-139 - Drug Profile
tipelukast - Drug Profile
tralokinumab - Drug Profile
YH-siRNA1 - Drug Profile
ZL-2101 - Drug Profile
ZL-2102 - Drug Profile
Idiopathic Pulmonary Fibrosis - Recent Pipeline Updates
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2015
Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Biogen, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corporation, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corporation, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Histocell S.L., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by iBio, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva SAS, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corporation, LLC, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Private Limited, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Progenra, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Promedior, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics, Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc., H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Idiopathic Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015
Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2015
Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..1), H2 2015
Idiopathic Pulmonary Fibrosis - Dormant Projects (Contd..2), H2 2015
Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2015
Number of Products under Development for Idiopathic Pulmonary Fibrosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report